Choline phospholipid metabolism: A target in cancer cells?

Research output: Contribution to journalArticle

Abstract

The experience of treating cancer over the past several decades overwhelmingly demonstrates that the disease continues to evade the vast array of drugs and treatment modalities available in the twenty-first century. This is not surprising in view of the complexity of this disease, and the multiplicities of pathways available to the cancer cell to enable its survival. Although the progression of cancer arrives at a common end point of cachexia, organ failure, and death, common pathways are rare in cancer. Identifying and targeting common pathways that would act across these levels of multiplicity is essential for the successful treatment of this disease. Over the past decade, one common characteristic consistently revealed by rhagnetic resonance spectroscopic studies is the elevation of phosphocholine and total choline-containing compounds in cancer cells and solid tumors. This elevation has been observed in almost every single cancer type studied with NMR spectroscopy and can be used as an endogenous biomarker of cancer. In this article, we have summarized some of the observations on the choline phospholipid metabolism of cancer cells and tumors, and make a case for targeting the aberrant choline phospholipid metabolism of cancer cells.

Original languageEnglish (US)
Pages (from-to)525-533
Number of pages9
JournalJournal of Cellular Biochemistry
Volume90
Issue number3
DOIs
StatePublished - Oct 15 2003

Fingerprint

Choline
Metabolism
Phospholipids
Cells
Tumors
Neoplasms
Phosphorylcholine
Tumor Biomarkers
Nuclear magnetic resonance spectroscopy
Cachexia
Pharmaceutical Preparations
Magnetic Resonance Spectroscopy

Keywords

  • Cancer
  • Choline phospholipid metabolism
  • Magnetic resonance

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology

Cite this

Choline phospholipid metabolism : A target in cancer cells? / Ackerstaff, Ellen; Glunde, Kristine; Bhujwalla, Zaver M.

In: Journal of Cellular Biochemistry, Vol. 90, No. 3, 15.10.2003, p. 525-533.

Research output: Contribution to journalArticle

@article{20d5c14c6c214c2abb5ef436f122e4dd,
title = "Choline phospholipid metabolism: A target in cancer cells?",
abstract = "The experience of treating cancer over the past several decades overwhelmingly demonstrates that the disease continues to evade the vast array of drugs and treatment modalities available in the twenty-first century. This is not surprising in view of the complexity of this disease, and the multiplicities of pathways available to the cancer cell to enable its survival. Although the progression of cancer arrives at a common end point of cachexia, organ failure, and death, common pathways are rare in cancer. Identifying and targeting common pathways that would act across these levels of multiplicity is essential for the successful treatment of this disease. Over the past decade, one common characteristic consistently revealed by rhagnetic resonance spectroscopic studies is the elevation of phosphocholine and total choline-containing compounds in cancer cells and solid tumors. This elevation has been observed in almost every single cancer type studied with NMR spectroscopy and can be used as an endogenous biomarker of cancer. In this article, we have summarized some of the observations on the choline phospholipid metabolism of cancer cells and tumors, and make a case for targeting the aberrant choline phospholipid metabolism of cancer cells.",
keywords = "Cancer, Choline phospholipid metabolism, Magnetic resonance",
author = "Ellen Ackerstaff and Kristine Glunde and Bhujwalla, {Zaver M.}",
year = "2003",
month = "10",
day = "15",
doi = "10.1002/jcb.10659",
language = "English (US)",
volume = "90",
pages = "525--533",
journal = "Journal of Cellular Biochemistry",
issn = "0730-2312",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Choline phospholipid metabolism

T2 - A target in cancer cells?

AU - Ackerstaff, Ellen

AU - Glunde, Kristine

AU - Bhujwalla, Zaver M.

PY - 2003/10/15

Y1 - 2003/10/15

N2 - The experience of treating cancer over the past several decades overwhelmingly demonstrates that the disease continues to evade the vast array of drugs and treatment modalities available in the twenty-first century. This is not surprising in view of the complexity of this disease, and the multiplicities of pathways available to the cancer cell to enable its survival. Although the progression of cancer arrives at a common end point of cachexia, organ failure, and death, common pathways are rare in cancer. Identifying and targeting common pathways that would act across these levels of multiplicity is essential for the successful treatment of this disease. Over the past decade, one common characteristic consistently revealed by rhagnetic resonance spectroscopic studies is the elevation of phosphocholine and total choline-containing compounds in cancer cells and solid tumors. This elevation has been observed in almost every single cancer type studied with NMR spectroscopy and can be used as an endogenous biomarker of cancer. In this article, we have summarized some of the observations on the choline phospholipid metabolism of cancer cells and tumors, and make a case for targeting the aberrant choline phospholipid metabolism of cancer cells.

AB - The experience of treating cancer over the past several decades overwhelmingly demonstrates that the disease continues to evade the vast array of drugs and treatment modalities available in the twenty-first century. This is not surprising in view of the complexity of this disease, and the multiplicities of pathways available to the cancer cell to enable its survival. Although the progression of cancer arrives at a common end point of cachexia, organ failure, and death, common pathways are rare in cancer. Identifying and targeting common pathways that would act across these levels of multiplicity is essential for the successful treatment of this disease. Over the past decade, one common characteristic consistently revealed by rhagnetic resonance spectroscopic studies is the elevation of phosphocholine and total choline-containing compounds in cancer cells and solid tumors. This elevation has been observed in almost every single cancer type studied with NMR spectroscopy and can be used as an endogenous biomarker of cancer. In this article, we have summarized some of the observations on the choline phospholipid metabolism of cancer cells and tumors, and make a case for targeting the aberrant choline phospholipid metabolism of cancer cells.

KW - Cancer

KW - Choline phospholipid metabolism

KW - Magnetic resonance

UR - http://www.scopus.com/inward/record.url?scp=0141954157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141954157&partnerID=8YFLogxK

U2 - 10.1002/jcb.10659

DO - 10.1002/jcb.10659

M3 - Article

C2 - 14523987

AN - SCOPUS:0141954157

VL - 90

SP - 525

EP - 533

JO - Journal of Cellular Biochemistry

JF - Journal of Cellular Biochemistry

SN - 0730-2312

IS - 3

ER -